CePT creates Center for Regenerative and Translational Medicine

Center for Preclinical Research and Technology (CePT) creates Center for Regenerative Medicine and Center for Translational Medicine in Warsaw. Their creation will accelerate the development of Polish biomedicine by 20 years. These are the first centers in Poland to comprehensively focus on research and implementation of innovative therapies related to nanotechnology, tissue and genetic engineering and the use of stem cells in the fight against civilization diseases, m.in. with tumors.

Until a dozen years ago, Poland was a complete desert when it came to the sector of modern biomedical companies. At the moment, biomedicine is one of the fastest growing sectorsoin the country, although it is still an emerging sector. As reported by Glowny Statistical Office, in 2016 alone, the number of biotechnology start-ups increased by 15 percent. In turn, scientific and research centers such as CePT, in terms of infrastructure and scientific facilities, can compete with the leading biotechnology centers in Europe and the world.

– We managed to build a proper infrastructure and great research teams. We have the potential to become a world-leading scientific and research center. Our establishment of the Center for Regenerative Medicine and the Center for Translational Medicine is another step in this direction – emphasizes prof. dr hab. n. farms. Jadwiga Turło, Prorector of Ds. The research group of the Warsaw Medical University’s Department of Science and Technology Transfer, the leader of the CePT project – the largest biomedical center in Central and Eastern Europe.

Regenerative medicine is currently one of the leading and most promising trendsoin biomedicine. The establishment of the Center for Regenerative Medicine in Poland offers great therapeutic possibilities and creates hope for the treatment of a number of diseases through the use of embryonic cellsostem cells of the human body, e.g. skin burnsornych, blood system disordersorczego, damage to the heart muscle, liver or someorych disorders of the central nervous system, regeneration of organsoin and aging tissues.

Poland has already made a significant contribution to the development ofoj this field of medicine. It is the teamoł scientistsoUnder the direction of prof. dr hab. Mariusz Ratajczak discovered that adult tissues contain a population of small comostem cells resembling comoembryonic cells, whichore can be used in tissue regeneration. They have been named VSELs (very small embryonic like stem cells). After many years of working in the US, prof. Ratajczak will continue his research in Poland.

– At the Center for Regenerative Medicine, we will m.in. Optimize the methods of using the comoVSELs stem cells. RoIn parallel, in wspon cooperation with chemists and pharmacists, we want to develop a new generation of stem cell drugsow, whichore would improve „condition” comostem cells, mainlyownie those whoore in our body are involved in regenerating organsoin and aging tissues. We aspire to create a new branch of biomedical science – so-called. pharmacology of comostem cells – mowi prof. Dr. hab. Mariusz Ratajczak, Head of the Center for Regenerative Medicine.

Developoj regenerative medicine in Poland is also an opportunity for the Polish economy. The game is worth the candle. In 2017, the global comostem cells have reached a value of $65 billion, and America PoNorth now accounts for 60 percent of. of this market. The European Regenerative Medicine market is expected to reach a ceiling of $24.2 billion by 2021, up from $8.6 billion in 2016. The question is what is Poland’s real chance to become a shareholder of profitableow of this market? Teamoł prof. Ratajczak has the relevant patents and intellectual property rights to the discovered cellularoVSELs records, which gives good prospects for the appearance of Polish regenerative medicine on the global market.

In turn, the Center for Translational Medicine will focus on accelerating the introduction of the result ofoin biomedical experimentsow for patient therapyow. One of the therapies thatore to be developed at this Center is an innovative CAR-T strategy, used to fight cancerous.

CAR-T therapy is one of the latest medical advances. The method is based on a combination of targeted therapy, personalized medicine and immunotherapy. Komorki of the immune system (T lymphocytes) of patients is turned into a "living medicines" – taken from the patient’s own T lymphocytes, i.e., comorki created to combat roinfections in the body, are genetically modified in the lab and then properly enhanced to fight comocancerous tumors, return to the patient’s blood to identify and destroy enemy. Spectacular effects of this therapy can be seen in the treatment of acute lymphoblastic leukemia – up to 90 percent. complete remissions. In August 2017, the US registered the world’s first CAR-T treatment for patientow with acute lymphoblastic leukemia.

Warsaw Medical University’s research group under the cool under the leadership of prof. Jakub Gołąb, Ph. Magdalena Winiarska and Dr. hab. Radoslaw Zagozdzon, ktora will work at the Center for Translational Medicine at CePT, over the years it has attracted domestic and foreign funding to gain know-how at the world’s top biotechnology centers. In cooperationoCooperation with a team of cliniciansow (under the leadership of Dr. hab. Grzegorz Basak), researchers from this group want to develop CAR-T therapy and CAR-NK therapy in Poland, in which theyoThe comoNK (natural killers), – that may be more effective than T cells.

– We are at the stage of creating the structure of the Center for Translational Medicine and completing the teamoin research. In the optimistic version, we assume that within 3-5 years of operational efficiency we will have candidates for CAR-T or CAR-NK therapies for Polish patientsow. – emphasizes Dr. hab. n. med. Radosław Zagożdżon, head of the Department of Clinical Immunology at the Institute of Transplantation at Warsaw Medical University.

For Polish patientsow is the hope for greater availability of CAR-T therapies. This therapy involves a complex and expensive technological process. Currently, the cost of a single CAR-T therapy in the United States is nearly 500,000. dollarow. How much could it cost in Poland? It is estimated that initially CAR-T therapy in our country would cost about 150 thousand. dollarow.

DetailsoThe creation of the Centroin Regenerative and Translational Medicine will be announced at the 7th conference „CePT- Platform for the development of innovative biomedicine 2018”, April 17 this year. at the Didactic Center of the Warsaw Medical University.

Opening of the CenteroIn Regenerative and Translational Medicine are not the only issues thatore will be discussed during the VII Conference „CePT – a platform for the development of innovative biomedicine 2018”. Each year, the Center for Preclinical Research and Technology is involved in a number of projectsow, whichore aiming to create unique solutions, whichore may in the future find application in the treatment of major diseases of civilization and improve the quality of lifeob civilization diseases and improve the quality of life of Polesow. Therefore, one of the key elementsoin the conference will be the presentation of the latest projectoin research conducted by scientists ofow with CePT, supporting industry in developing new drugsoin and therapies.

An important topic thatory will be discussed at the conference, is the problem of technology transfer and valuation of intellectual property, ways to reduce the risks associated with the implementation of R&D work, as roThe meeting was organized by the University of Silesia in early JuneoThe funding sources for the projectoin research and programow, which would allow to increase the area ofoin wspocooperation of scientistsoin with entrepreneurs.

The conference will be attended by representatives of the world of science, companies and investors from all over Poland operating in the field of Life Science, as well as representatives of state and local administration.

CePT is currently the largest investment in science in Poland and the largest biomedical center in Central and Eastern Europe. They are created by: Warsaw Medical University, University of Warsaw, Warsaw University of Technology, Nencki Institute of PAN, Institute of Biochemistry and Biophysics of PAN, Institute of Experimental and Clinical Medicine of im. M. Mossakovsky Institute of the Polish Academy of Sciences, International Institute of Molecular Biology and ComoThe Institute of Fundamental Problemsoin Technology of the Polish Academy of Sciences, Institute of High Pressure Physics of the Polish Academy of Sciences, Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences.